



Noxopharm AGM 2022 Chair's Address

Sydney, 17 November 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** provides Noxopharm Non-Executive Chairman, Mr Frederick Bart's address to the 2022 Annual General Meeting of Shareholders.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its clinical drug candidate Veyonda[®], plus two innovative technology platforms – Chroma[™] (oncology) and Sofra[™] (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm 2022 AGM Chairman's Address

Fellow Shareholders,

I am delighted to welcome you to the 2022 Annual General Meeting for Noxopharm.

It is a pleasure to return to the in-person setting after the past few years' disruption, and we welcome the chance to talk personally with those shareholders in attendance.

We would also like to thank our shareholders for their ongoing support, especially as we continue to evolve the company and develop a business with a robust pipeline of commercial opportunities in three main areas.

A lot has happened since our last AGM, with one of the major developments being the departure of our founder and CEO, Dr Graham Kelly, and the appointment of Dr Gisela Mautner as his replacement at the start of this year.

Dr Mautner has extensive international experience working in leadership roles for a number of the world's largest pharmaceutical companies. She knows their culture and the way they think, and also has an in-depth understanding of the complexities of scientific research and clinical trials.

Additionally, she has a strong management team supporting her, all of whom have extensive experience and expertise in their respective fields. It's important to note that this team works collaboratively and openly every day to deliver value for our shareholders.

From the work undertaken since our founding, we are now at the point where Veyonda is the subject of three ongoing clinical trials involving some of the world's leading cancer centres.

This is a major undertaking, as getting such prestigious institutions on board, and then screening and recruiting patients, is an onerous one that has involved the significant commitment of resources and time from both Noxopharm and the participating hospitals.

The company is making every effort to keep things moving as quickly as possible, and we are pleased to note that these safety phases are progressing as expected, and we continue to notify the market when each milestone is met.

We have also seen progress in the development of our two proprietary R&D platforms, namely Chroma™ and Sofra™.

These two platforms are vital to our future, because they represent core technologies on top of which many individual drug development programs can be built.

We have seen the early fruits of the Chroma™ platform as recently as this past September, when we revealed promising results from a trial with UNSW Sydney regarding a new

pancreatic drug. While it is still early days, this kind of research, and the drug's unique dual-cell therapy characteristics, show the depth of expertise inherent in the Noxopharm team, and the scientific skills we are bringing to bear in exciting new ways.

The same can be said of the Sofra™ platform, which incorporates our Pharmorage subsidiary and is mostly related to inflammation. While we are still undertaking several studies and other activities in this area with our partners, we note that the mRNA space in particular is seeing a lot of activity, driven by the COVID vaccine and other medical developments. We have technology under development with our strategic partner, Melbourne's Hudson Medical Research Institute, that is showing potential to play a role in the mRNA vaccine supply chain, and so we will continue to progress our research in this field as quickly as possible.

For their continuing hard work, I would like to pay tribute to all of our staff. While shareholders often have visibility of the management team, there are others who are working diligently and creatively in everything from designing innovative new molecules to building strong relationships with our clinical trial partners, and their determination to deliver results should be recognised.

Finally, on behalf of the Noxopharm Board, I take this opportunity to express our thanks and appreciation to the shareholders for your ongoing patience and support as the Company continues its advance towards its commercial goals.

Yours sincerely,



Fred Bart
17 November 2022